CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%

The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half

Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency

The accelerated review covers WCK 5222 for multiple critical infections

CPHI & PMEC India 2025 ignites pharma innovation and partnerships

For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows

Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries

Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia

Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year

This recognition demonstrate excellence in intellectual property (IP) value creation.

Emcure Pharmaceuticals appoints Barnona Basu as Director – Marketing (India)

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones

ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules

Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)

FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich

This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA

Apollo Pharmacy becomes 7,000-store strong

The 7,000th store was inaugurated in Ayodhya, Uttar Pradesh